• English
  • 中文繁体
  • 中文简体
Hi,
moomoo ID:NaN
Log Out
donwloadimg

Download App

Log in to access Online Inquiry
Quotes
Detailed Quotes
Company Overview
Company ProfileCompany Executives
Financial Analysis
Main CompositionKey IndicatorsFinancial Statement
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > KNSA Kiniksa Pharmaceuticals > Detailed Quotes

KNSA Kiniksa Pharmaceuticals

10.300
-0.380-3.56%
Close 06/24 16:00 ET
10.30000.00%
Post Mkt Price 06/24 16:16 ET
High
10.960
Open
10.570
Turnover
6.12M
Low
10.165
Pre Close
10.680
Volume
590.31K
Market Cap
713.54M
P/E(TTM)
Loss
52wk High
16.679
Shares
69.28M
P/E(Static)
Loss
52wk Low
7.360
Float Cap
275.39M
Bid/Ask %
-66.67%
Historical High
32.880
Shs Float
26.74M
Volume Ratio
1.24
Historical Low
5.010
Dividend TTM
--
Div Yield TTM
35
P/B
4.29
Dividend LFY
--
Div Yield LFY
339.81%
Turnover Ratio
2.21%
Amplitude
7.44%
Avg Price
10.374
Lot Size
1
Float Cap
275.39M
Bid/Ask %
-66.67%
Historical High
32.880
Shs Float
26.74M
Volume Ratio
1.24
Historical Low
5.010
Dividend TTM
--
P/B
4.29
Dividend LFY
--
Turnover Ratio
2.21%
Amplitude
7.44%
Avg Price
10.374
Lot Size
1
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast

No Data

News

Comment

News

Announcement

All

Earnings Report

Related Transactions

Changes In Ownership

Major Events

Other

Company Overview More
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
CEO： Patel, Sanj K.
Market： NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...